|
US8993808B2
(en)
|
2009-01-21 |
2015-03-31 |
Oryzon Genomics, S.A. |
Phenylcyclopropylamine derivatives and their medical use
|
|
WO2011035941A1
(en)
|
2009-09-25 |
2011-03-31 |
Oryzon Genomics S.A. |
Lysine specific demethylase-1 inhibitors and their use
|
|
US8946296B2
(en)
|
2009-10-09 |
2015-02-03 |
Oryzon Genomics S.A. |
Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
|
|
WO2011106574A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Inhibitors for antiviral use
|
|
WO2011106106A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
|
|
RS55348B1
(sr)
|
2010-04-19 |
2017-03-31 |
Oryzon Gnomics S A |
Inhibitori lizin specifične demetilaze-1 i njihova upotreba
|
|
DK2598482T3
(en)
|
2010-07-29 |
2018-06-14 |
Oryzon Genomics Sa |
ARYLCYCLOPROPYLAMINE-BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE
|
|
EP2598480B1
(en)
|
2010-07-29 |
2019-04-24 |
Oryzon Genomics, S.A. |
Cyclopropylamine derivatives useful as lsd1 inhibitors
|
|
WO2012045883A1
(en)
|
2010-10-08 |
2012-04-12 |
Oryzon Genomics S.A. |
Cyclopropylamine inhibitors of oxidases
|
|
WO2012072713A2
(en)
|
2010-11-30 |
2012-06-07 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
|
|
EP2712315B1
(en)
|
2011-02-08 |
2021-11-24 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for myeloproliferative disorders
|
|
BR112014002939A2
(pt)
*
|
2011-08-09 |
2017-03-01 |
Takeda Pharmaceuticals Co |
composto, medicamento, método para profilaxia ou tratamento de doença, a doença sendo esquizofrenia, alzheimer, parkinson ou huntington, uso do composto, e, método para inibir o lsd1
|
|
US9469597B2
(en)
|
2011-10-20 |
2016-10-18 |
Oryzon Genomics S.A. |
(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
|
|
AU2012324803B9
(en)
|
2011-10-20 |
2017-08-24 |
Oryzon Genomics, S.A. |
(hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
|
|
ES2654143T3
(es)
|
2012-10-02 |
2018-02-12 |
Gilead Sciences, Inc. |
Inhibidores de desmetilasas de histonas
|
|
EP2907802B1
(en)
|
2012-10-12 |
2019-08-07 |
Takeda Pharmaceutical Company Limited |
Cyclopropanamine compound and use thereof
|
|
EP2740474A1
(en)
|
2012-12-05 |
2014-06-11 |
Instituto Europeo di Oncologia S.r.l. |
Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
|
|
SG10201707027SA
(en)
|
2013-02-27 |
2017-09-28 |
Epitherapeutics Aps |
Inhibitors of histone demethylases
|
|
US9918983B2
(en)
*
|
2013-05-30 |
2018-03-20 |
The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas |
Suicidal LSD1 inhibitors targeting SOX2-expressing cancer cells
|
|
WO2015012515A1
(ko)
*
|
2013-07-25 |
2015-01-29 |
동아에스티 주식회사 |
벤즈아미드 유도체의 제조방법, 그의 제조에 사용되는 새로운 중간체 및 상기 중간체의 제조방법
|
|
JP6521967B2
(ja)
|
2013-08-06 |
2019-05-29 |
イマーゴ バイオサイエンシーズ インコーポレイテッド |
疾患の治療のためのｋｄｍ１ａ阻害剤
|
|
EP3392244A1
(en)
|
2014-02-13 |
2018-10-24 |
Incyte Corporation |
Cyclopropylamines as lsd1 inhibitors
|
|
LT3105218T
(lt)
|
2014-02-13 |
2019-12-10 |
Incyte Corp |
Ciklopropilaminai kaip lsd1 inhibitoriai
|
|
WO2015123424A1
(en)
|
2014-02-13 |
2015-08-20 |
Incyte Corporation |
Cyclopropylamines as lsd1 inhibitors
|
|
US9527835B2
(en)
|
2014-02-13 |
2016-12-27 |
Incyte Corporation |
Cyclopropylamines as LSD1 inhibitors
|
|
CN104042616B
(zh)
*
|
2014-02-20 |
2016-08-24 |
复旦大学附属眼耳鼻喉科医院 |
赖氨酸特异性去甲基化酶1抑制剂的应用
|
|
NZ725262A
(en)
|
2014-04-11 |
2023-01-27 |
Takeda Pharmaceuticals Co |
Cyclopropanamine compound and use thereof
|
|
WO2015168466A1
(en)
|
2014-05-01 |
2015-11-05 |
Quanticel Pharmaceuticals, Inc. |
Inhibitors of lysine specific demethylase-1
|
|
WO2016007722A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as lsd1 inhibitors
|
|
WO2016007731A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Imidazopyridines and imidazopyrazines as lsd1 inhibitors
|
|
US9758523B2
(en)
|
2014-07-10 |
2017-09-12 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as LSD1 inhibitors
|
|
WO2016007736A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Imidazopyrazines as lsd1 inhibitors
|
|
JP2017526675A
(ja)
|
2014-08-27 |
2017-09-14 |
ギリアード サイエンシーズ， インコーポレイテッド |
ヒストンデメチラーゼを阻害するための化合物および方法
|
|
WO2016055935A1
(en)
*
|
2014-10-06 |
2016-04-14 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
|
|
EA039196B1
(ru)
*
|
2014-10-08 |
2021-12-16 |
Инсайт Корпорейшн |
Циклопропиламины в качестве ингибиторов lsd1
|
|
EP3250552B1
(en)
*
|
2015-01-30 |
2019-03-27 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
JP6727216B2
(ja)
|
2015-02-12 |
2020-07-22 |
イマーゴ バイオサイエンシーズ インコーポレイテッド |
疾患の治療のためのｋｄｍ１ａ阻害剤
|
|
EA201792205A1
(ru)
|
2015-04-03 |
2018-02-28 |
Инсайт Корпорейшн |
Гетероциклические соединения как ингибиторы lsd1
|
|
EP3286172B1
(en)
|
2015-04-23 |
2019-06-12 |
Constellation Pharmaceuticals, Inc. |
Lsd1 inhibitors and uses thereof
|
|
EP3090998A1
(en)
|
2015-05-06 |
2016-11-09 |
F. Hoffmann-La Roche AG |
Solid forms
|
|
KR20180011331A
(ko)
|
2015-06-12 |
2018-01-31 |
오리존 지노믹스 에스.에이. |
Lsd1 억제제와 관련된 바이오마커 및 그의 용도
|
|
WO2017013061A1
(en)
|
2015-07-17 |
2017-01-26 |
Oryzon Genomics, S.A. |
Biomarkers associated with lsd1 inhibitors and uses thereof
|
|
DK3334709T3
(da)
*
|
2015-08-12 |
2025-02-03 |
Incyte Holdings Corp |
Salte af en lsd1-hæmmer
|
|
WO2017035271A1
(en)
|
2015-08-27 |
2017-03-02 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
|
WO2017079476A1
(en)
*
|
2015-11-05 |
2017-05-11 |
Mirati Therapeutics, Inc. |
Lsd1 inhibitors
|
|
US10899732B2
(en)
|
2015-11-25 |
2021-01-26 |
Genentech, Inc. |
Substituted benzamides useful as sodium channel blockers
|
|
WO2017097865A1
(en)
*
|
2015-12-07 |
2017-06-15 |
Istituto Europeo Di Oncologia |
Combination of caloric restriction (cr) or igf1/insulin receptor inhibitor with lsd1 inhibitor
|
|
KR102720551B1
(ko)
*
|
2015-12-29 |
2024-10-21 |
미라티 테라퓨틱스, 인크. |
Lsd1 억제제
|
|
KR20180099768A
(ko)
|
2015-12-30 |
2018-09-05 |
노파르티스 아게 |
증진된 효능을 갖는 면역 이펙터 세포 요법
|
|
SG10201913290QA
(en)
|
2016-03-15 |
2020-03-30 |
Oryzon Genomics Sa |
Combinations of lsd1 inhibitors for the treatment of hematological malignancies
|
|
CN120661674A
(zh)
|
2016-03-15 |
2025-09-19 |
奥莱松基因组股份有限公司 |
用于治疗实体瘤的lsd1抑制剂的组合
|
|
JP2019512546A
(ja)
*
|
2016-03-16 |
2019-05-16 |
オリゾン・ゲノミクス・ソシエダッド・アノニマ |
Ｋｄｍ１ａ標的会合を決定するための方法、およびそれに有用な化学プローブ
|
|
CN107200706A
(zh)
|
2016-03-16 |
2017-09-26 |
中国科学院上海药物研究所 |
一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途
|
|
US10766858B2
(en)
|
2016-03-30 |
2020-09-08 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
|
CA3021678A1
(en)
|
2016-04-22 |
2017-10-26 |
Incyte Corporation |
Formulations of an lsd1 inhibitor
|
|
CN107459476B
(zh)
*
|
2016-06-03 |
2022-06-24 |
中国科学院上海药物研究所 |
反吲哚啉环丙胺类化合物及其制备方法、药物组合物和用途
|
|
SI3307267T1
(sl)
|
2016-06-10 |
2019-08-30 |
Oryzon Genomics, S.A. |
Zdravljenje multiple skleroze
|
|
WO2018020366A1
(en)
|
2016-07-26 |
2018-02-01 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Crystalline (r)-mandelate salt of (1r,2s)-2-phenylcyclopropylamine
|
|
SG10201610038SA
(en)
*
|
2016-07-29 |
2017-12-28 |
Apple Inc |
Systems and methods for management of asymmetrical multi-tapped battery packs
|
|
CN111194306B
(zh)
|
2016-08-16 |
2023-05-16 |
伊美格生物科学公司 |
用于制备kdm1a抑制剂的方法和过程
|
|
BR112019007763A2
(pt)
|
2016-10-17 |
2019-07-02 |
Genentech Inc |
composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção
|
|
US20190256929A1
(en)
|
2016-11-03 |
2019-08-22 |
Oryzon Genomics, S.A. |
Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
|
|
US20190256930A1
(en)
|
2016-11-03 |
2019-08-22 |
Oryzon Genomics, S.A. |
Biomarkers for determining responsiveness to lsd1 inhibitors
|
|
WO2018106984A1
(en)
|
2016-12-09 |
2018-06-14 |
Constellation Pharmaceuticals, Inc. |
Markers for personalized cancer treatment with lsd1 inhibitors
|
|
WO2018137644A1
(zh)
*
|
2017-01-24 |
2018-08-02 |
南京明德新药研发股份有限公司 |
Lsd1抑制剂及其制备方法和应用
|
|
EP3601273B1
(en)
|
2017-03-24 |
2021-12-01 |
Genentech, Inc. |
4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
|
|
WO2018197583A1
(en)
|
2017-04-26 |
2018-11-01 |
Istituto Europeo Di Oncologia |
Use of a combinational therapy of lsd1 inhibitors with p21 activators in the treatment of cancer
|
|
WO2018216795A1
(ja)
|
2017-05-26 |
2018-11-29 |
大鵬薬品工業株式会社 |
新規なビフェニル化合物を用いた抗腫瘍効果増強剤
|
|
RU2765152C2
(ru)
|
2017-05-26 |
2022-01-26 |
Тайхо Фармасьютикал Ко., Лтд. |
Новое соединение бифенила или его соль
|
|
AU2018276611B2
(en)
|
2017-05-31 |
2022-01-06 |
Taiho Pharmaceutical Co., Ltd. |
Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1
|
|
KR20180134675A
(ko)
*
|
2017-06-09 |
2018-12-19 |
한미약품 주식회사 |
시클로프로필아민 유도체 화합물 및 이의 용도
|
|
JP2020152641A
(ja)
*
|
2017-07-07 |
2020-09-24 |
国立研究開発法人理化学研究所 |
リジン特異的脱メチル化酵素１阻害活性を有する新規化合物、その製造方法及びその用途
|
|
AU2018309372B2
(en)
|
2017-08-03 |
2024-08-15 |
Oryzon Genomics, S.A. |
Methods of treating behavior alterations
|
|
AR112900A1
(es)
|
2017-09-13 |
2019-12-26 |
Hanmi Pharm Ind Co Ltd |
Compuesto derivado de pirazol y uso de este
|
|
WO2019068326A1
(en)
|
2017-10-05 |
2019-04-11 |
Université D'aix-Marseille |
INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES
|
|
KR20190040763A
(ko)
|
2017-10-11 |
2019-04-19 |
한미약품 주식회사 |
피라졸로피리딘 유도체 화합물 및 이의 용도
|
|
KR20190040783A
(ko)
|
2017-10-11 |
2019-04-19 |
한미약품 주식회사 |
라이신 특이적 데메틸라제-1 억제제로서의 피라졸 유도체
|
|
US11685782B2
(en)
|
2017-10-23 |
2023-06-27 |
Children's Medical Center Corporation |
Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
|
|
WO2019109095A1
(en)
*
|
2017-12-01 |
2019-06-06 |
Beth Israel Deaconess Medical Center, Inc. |
Arsenic trioxide and retinoic acid compounds for treatment of idh2-associated disorders
|
|
CN108107199B
(zh)
*
|
2017-12-21 |
2019-02-12 |
广州市进德生物科技有限公司 |
一种酶化学发光法测定尿酸的检测试剂盒
|
|
AR114263A1
(es)
|
2018-02-26 |
2020-08-12 |
Genentech Inc |
Compuestos terapéuticos y métodos para utilizarlos
|
|
WO2019191702A1
(en)
|
2018-03-30 |
2019-10-03 |
F. Hoffmann-La Roche Ag |
Substituted hydro-pyrido-azines as sodium channel inhibitors
|
|
JP7450559B2
(ja)
|
2018-05-11 |
2024-03-15 |
イマーゴ バイオサイエンシーズ インコーポレイテッド |
疾患の処置のためのｋｄｍ１ａ阻害剤
|
|
TW202003490A
(zh)
|
2018-05-22 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
|
KR102778948B1
(ko)
*
|
2018-07-20 |
2025-03-07 |
씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 |
Lsd1억제제의 염 및 이의 결정형
|
|
US10968200B2
(en)
|
2018-08-31 |
2021-04-06 |
Incyte Corporation |
Salts of an LSD1 inhibitor and processes for preparing the same
|
|
CN112672994B
(zh)
*
|
2018-09-13 |
2022-09-13 |
南昌弘益药业有限公司 |
作为lsd1抑制剂的杂螺环类化合物及其应用
|
|
CN112689638B
(zh)
*
|
2018-09-13 |
2022-11-08 |
南昌弘益药业有限公司 |
作为lsd1抑制剂的环丙胺类化合物及其应用
|
|
US20220024891A1
(en)
*
|
2018-12-04 |
2022-01-27 |
The Board Of Regents Of The University Of Texas System |
Therapeutics targeting mutant adenomatous polyposis coli (apc) for the treatment of cancer
|
|
WO2020138398A1
(ja)
*
|
2018-12-28 |
2020-07-02 |
国立研究開発法人理化学研究所 |
リジン特異的脱メチル化酵素１を阻害する新規化合物、その製造方法及びその用途
|
|
US12479845B2
(en)
|
2019-02-01 |
2025-11-25 |
Hanmi Pharm. Co., Ltd. |
Imidazopyridine derivative compounds and use of same
|
|
AU2020216034B2
(en)
|
2019-02-01 |
2024-12-19 |
Hanmi Pharm. Co., Ltd. |
Imidazopyridine derivative compounds and use of same
|
|
SI3941466T1
(sl)
|
2019-03-20 |
2026-04-30 |
Oryzon Genomics, S.A. |
Vafidemstat za zdravljenje neagresivnih simptomov mejne osebnostne motnje
|
|
HRP20251471T1
(hr)
|
2019-03-20 |
2026-01-02 |
Oryzon Genomics, S.A. |
Postupci liječenja poremećaja hiperaktivnosti s deficitom pažnje korištenjem inhibitora kdm1a kao što je spoj vafidemstat
|
|
CN114341366A
(zh)
|
2019-07-05 |
2022-04-12 |
奥莱松基因组股份有限公司 |
用于使用kdm1a抑制剂个体化治疗小细胞肺癌的生物标志物和方法
|
|
CN114502561B
(zh)
*
|
2019-09-29 |
2023-12-26 |
南昌弘益药业有限公司 |
Lsd1抑制剂
|
|
US12035779B2
(en)
*
|
2020-05-28 |
2024-07-16 |
Nike, Inc. |
Foot support systems including fluid movement controllers and adjustable foot support pressure
|
|
EP3964204A1
(en)
|
2020-09-08 |
2022-03-09 |
Université d'Aix-Marseille |
Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues
|
|
WO2022171044A1
(zh)
*
|
2021-02-09 |
2022-08-18 |
南昌弘益药业有限公司 |
一种氧氮杂螺环化合物、其盐型及其晶型
|
|
CA3231846A1
(en)
|
2021-04-08 |
2022-10-13 |
Tamara Maes |
Combinations of lsd1 inhibitors for treating myeloid cancers
|
|
CN116888122B
(zh)
*
|
2021-06-22 |
2026-07-24 |
南昌弘益药业有限公司 |
含氮氧杂螺环类化合物及其应用
|
|
CN113512031B
(zh)
*
|
2021-07-01 |
2024-01-30 |
都创(上海)医药开发有限公司 |
一种lsd1酶抑制剂tak-418中间体化合物制备方法
|
|
GB202115017D0
(en)
|
2021-10-20 |
2021-12-01 |
Univ London Queen Mary |
Sequential treatments and biomarkers to reverse resistance to kinase inhibitors
|
|
EP4419093A1
(en)
|
2021-10-20 |
2024-08-28 |
Queen Mary University of London |
Sequential treatments and biomarkers to reverse resistance to kinase inhibitors
|
|
US20250275969A1
(en)
|
2022-05-09 |
2025-09-04 |
Oryzon Genomics, S.A. |
Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
|
|
US20250295660A1
(en)
|
2022-05-09 |
2025-09-25 |
Oryzon Genomics, S.A. |
Methods of treating nf1-mutant tumors using lsd1 inhibitors
|
|
US20260151399A1
(en)
|
2022-11-24 |
2026-06-04 |
Oryzon Genomics, S.A. |
Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
|
|
KR20260019479A
(ko)
|
2023-05-04 |
2026-02-10 |
레볼루션 메디슨즈, 인크. |
Ras 관련 질환 또는 장애를 위한 병용 요법
|
|
CN121889155A
(zh)
|
2023-08-07 |
2026-04-17 |
锐新医药公司 |
用于治疗ras蛋白相关疾病或病症的rmc-6291
|
|
CN117164465B
(zh)
*
|
2023-09-04 |
2025-07-01 |
郑州大学 |
一种苯基环丙胺类化合物及其制备方法和应用
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|
|
WO2026090116A2
(en)
|
2024-10-21 |
2026-04-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026090245A1
(en)
|
2024-10-22 |
2026-04-30 |
Revolution Medicines, Inc. |
Use of ras inhibitors for treating cancer
|
|
US20260108528A1
(en)
|
2024-10-22 |
2026-04-23 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2026106912A1
(en)
|
2024-11-12 |
2026-05-21 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026112260A1
(en)
|
2024-11-21 |
2026-05-28 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026122764A2
(en)
|
2024-12-06 |
2026-06-11 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026128688A2
(en)
|
2024-12-13 |
2026-06-18 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026161839A1
(en)
|
2025-01-27 |
2026-07-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|